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Abstract
Objective: An epilepsy mouse model for Tuberous Sclerosis Complex (TSC)
was developed and validated to investigate the mechanisms underlying epilepto-
genesis. Furthermore, the possible antiepileptogenic properties of commonly
used antiepileptic drugs (AEDs) and new compounds were assessed. Methods:
Tsc1 deletion was induced in CAMK2A-expressing neurons of adult mice. The
antiepileptogenic properties of commonly used AEDs and inhibitors of the
mTOR pathways were assessed by EEG recordings and by molecular read outs.
Results: Mice developed epilepsy in a narrow time window (10  2 days) upon
Tsc1 gene deletion. Seizure frequency but not duration increased over time. Sei-
zures were lethal within 18 days, were unpredictable, and did not correlate to
seizure onset, length or frequency, reminiscent of sudden unexpected death in
epilepsy (SUDEP). Tsc1 gene deletion resulted in a strong activation of the
mTORC1 pathway, and both epileptogenesis and lethality could be entirely pre-
vented by RHEB1 gene deletion or rapamycin treatment. However, other inhibi-
tors of the mTOR pathway such as AZD8055 and PF4708671 were ineffective.
Except for ketogenic diet, none of commonly used AEDs showed an effect on
mTORC1 activity. Vigabatrin and ketogenic diet treatment were able to signifi-
cantly delay seizure onset. In contrast, survival was shortened by lamotrigine.
Interpretation: This novel Tsc1 mouse model is highly suitable to assess the
efficacy of antiepileptic and -epileptogenic drugs to treat mTORC1-dependent
epilepsy. Additionally, it allows us to study the mechanisms underlying
mTORC1-mediated epileptogenesis and SUDEP. We found that early treatment
with vigabatrin was not able to prevent epilepsy, but significantly delayed sei-
zure onset.
Introduction
Tuberous Sclerosis Complex (TSC) is an autosomal domi-
nant multisystem disorder caused by an inactivating
mutation in either the TSC1 or TSC2 gene.1 The TSC1
and TSC2 genes encode for the proteins hamartin and
tuberin respectively, forming a complex that inhibits the
mammalian Target of Rapamycin Complex 1 (mTORC1)
through Ras homolog enriched in brain (RHEB).
TSC is characterized by the formation of benign
tumors, which affect multiple organ systems including the
skin, heart, lungs, kidney, and brain.2 In the brain, lesions
(referred to as tubers) are often linked to the presence of
seizures within TSC patients, however, other factors are
involved as well.3 Notably, studies in animal models show
that acute deletion of the Tsc1 gene in adult animals is
sufficient to induce epilepsy in the absence of discernable
pathology.4
Up to 80–90% of the TSC patients develop severe epi-
lepsy, causing a significant decrease in the quality of life
and a high morbidity.5,6 In the majority of TSC patients,
epilepsy develops in the first years of life, and is associ-
ated with poor intellectual outcome and a developmental
delay.7–9 Currently, vigabatrin is used as a first-line treat-
ment to suppress infantile spasms, in TSC.10 However,
two-thirds of the TSC patients do not reach sustained
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seizure remission, highlighting the need for better treat-
ment.11,12 Specific targeting of the mTOR pathway may
in particular be a promising treatment method. A recent
clinical study showed decreased seizure frequency in TSC
patients treated with mTOR inhibitors13,14 or with a keto-
genic diet,15 which has also been shown to act on mTOR
signaling. In addition, it might be profitable to start treat-
ment well before seizures occur, thereby interfering with
the process of epileptogenesis.16 Epileptogenesis is the
molecular and cellular process that ultimately leads to the
development of seizures or chronic epilepsy. However, it
is largely unknown to what extend current antiepileptic
drugs (AEDs) are effective in blocking (or delaying)
mTOR-driven epileptogenesis. A preclinical study would
ideally utilize animal models in which epileptogenesis
occurs in a well-defined molecular and temporal fashion.
Previously, we generated an indicable Tsc1 mouse
model in which Tsc1 was biallelic deleted throughout the
entire body, resulting in a hyperactive mTORC1 pathway
and spontaneous epilepsy4. However, seizure onset in this
model was still quite variable and loss of Tsc1 in periph-
eral tissues induced early lethality, unrelated to epilepsy.
Therefore, the first aim of this study was to develop and
characterize a Tsc1 mouse model that showed mTORC1-
dependent epileptic seizures in a well-defined time win-
dow, without the loss of Tsc1 in peripheral tissue. The
second aim was to test the seizure-suppressive and possi-
ble antiepileptogenic effects of commonly used AEDs as
well as novel drugs, by electroencephalogram (EEG)
recording and their effect on the mTOR pathway.
Material and Methods
Mice
Inducible Tsc1 knockout mice were generated by crossing
transgenic mice carrying tamoxifen inducible CreERT2
under control of the Camk2a promoter (Tg(Camk2a-cre/
ERT2)2Gsc; MGI:3759305) in the C57BL/6J background17
with conditional biallelic floxed Tsc1 mutant mice
(Tsc1tm1Djk; MGI:2656240).18 These latter mice were
obtained in a mixed N2F5 background from Jackson Lab-
oratories and after three crosses into C57BL/6J main-
tained by interbreeding. This resulted in Tsc1f/f-Tg
(Camk2a-CreERT2+) and Tsc1f/f-Tg(Camk2a-CreERT2–)
mice, hereafter named Tsc1-Cre+ and Tsc1-Cre– mice
respectively. Tsc1-Cre– mice were negative for Cre recom-
binase and used as control throughout all experiments.
Inducible double knock out mice, in which both Tsc1 and
Rheb1 were deleted upon tamoxifen injections, were cre-
ated by crossing the Tsc1f/f-Tg(Camk2a-CreERT2+) mice
with a Rhebf/f mouse line (Rhebtm1Yelg; MGI:5752310) in
the C57BL/6J background.19
Gene deletion was induced in male and female 12- to
20-week-old mice. Mice were housed in individual venti-
lated cages and kept on a 12-h light/dark cycle, at
22  2°C and had ad libitum access to food and water.
Animal welfare was checked daily by animal caretakers
and experimenters throughout the experiments. For each
experiment, independent groups of mice were used. Only
the mice used for EEG measurements were single housed.
All cages contained basic bedding and nesting material.
For the EEG experiments, groups of at least six mice were
used and were sacrificed the latest on day 29 after gene
deletion. Mice used for the western blot experiment were
sacrificed on day 12 or 13 after gene deletion (indicated
in the figure legend). All experiments were approved by
the local animal experimentation center, in accordance
with institutional animal care and use guidelines (license
AVD1010020172684).
Immunohistochemistry and western blot
analysis
Samples for immunohistochemstry and western blot anal-
ysis were prepared as described previously.4 To analyze
the immunohistochemistry sections, a brightfield (CX41,
Olympus, Japan) or a confocal microscope (Zeiss,
LSM700) was used. Soma sizes were quantified in single-
section pictures with Zen (Zeiss, version 7.0). For western
blot analysis, mice were sacrificed 2 h after AED adminis-
tration. Lysates were prepared as described previously,4
and blots were imaged using a LI-COR Odyssey Scanner
system and quantified with Odyssey 3.0 software (LI-COR
Biosciences). Expression levels were corrected for actin
loading control and normalized to control mice.
Antibodies
Primary antibodies against CAMK2A (Novus Biologicals
NB100-1983, 1:500 for immunohistochemistry (IHC)),
Parvalbumin (SWANT, 1:9000 for IHC), NeuN ( 1:1000
IHC), TSC1 (CST #4906, 1:1000 for western blot),
RHEB1 (CST #4935, 1:1000 for western blot), pS6S240/
244 (CST #5634, 1:1000 for IHC, 1:2000 for western blot),
S6 (CST #2217, 1:2000 for western blot), pAktSer473
(CST #9271 1:2000 for western blot) and Actin (Chemi-
con MAB1501R, 1:20.000 for western blot) were used.
PathScan Akt antibody array
Mice were euthanized at day 8 or 13 by decapitation
under deep isoflurane anesthesia. Brains were dissected
and isolated cortical and hippocampal tissues were
homogenized in lysis buffer (0.02 mol/L Tris-HCl (pH
7.5), 0.15 mol/L NaCl, 0.001 mol/L Na2EDTA, 0.001 mol/
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L EGTA, 1% Triton, 0.02 mol/L sodium pyrophosphate,
0.025M sodium fluoride, 0.001 mol/L b-glycerophosphate,
0.001 mol/L Na3VO4, 1 lg/mL leupeptin, and protease
inhibitor cocktail (P8340, Sigma-Aldrich, 1:100). Samples
were analyzed using the PathScan Akt Signaling Antibody
Array Kit (CST#9700). With this kit, we assessed the
phosphorylation of the following proteins: Akt (T308,
S473), S6 (S235/236), AMPK-a (T172), PRAS40 (T246),
mTOR(S2481), GSK-3a (S21), GSK-3b (s9), p70S6K
(T389, T421/S424), Bad (S112), RSK1 (S380), PTEN
(S380), PDK1 (S241), Erk1/2 (T202/204), 4E-BP1 (T37/
46). LI-COR Odyssey fluorescence imaging system was
used to image the pad slide and Odyssey 3.0 software was
used for quantitative analyses (LI-COR Biosciences). The
obtained signals were corrected for actin loading control
and normalized to control mice.
EEG surgery and recordings
Mice were under anesthesia (2% isoflurane and 0.55% oxy-
gen) and injected with 20 lL rimadyl (Zoetis, 5 mg/mL),
an NSAID, to reduce pain and inflammation. Xilocaine
(AstraZeneca, 100 mg/mL) was sprayed on the skull as a
local anesthetic. In total, four EEG electrodes were placed
in the skull bilateral on top of the motor cortex (Bregma
AP: +1, ML: +1; AP: +1, ML: 1) and the somatosensory
cortex (Bregma: AP: 1, ML 4; AP: 1, ML: +4). A refer-
ence electrode was placed on the cerebellar cortex. At the
end of the surgery mice were injected with 50 lL temgesic
(Reckitt Benckiser, 0.3 mg/mL). Mice recovered for a week
from surgery before gene deletion was induced. For EEG
recordings, mice were connected to a wireless EEG recorder
(Neurologger, New behavior, TSE Systems) for 24 h per
day. EEG measurements were analyzed using Spike2 soft-
ware. A seizure was characterized by a rapid amplitude
increase, high spike frequency, and a typical postictal phase.
Seizure frequency for each mouse was averaged by day. The
day on which a mouse died, was not included in the num-
ber of seizure measurements.
Drugs
Tamoxifen (concentration 20 mg/mL) was dissolved in
sunflower oil and intraperitoneally injected for four con-
secutive days in all mice during the light phase of the day
(100 mg/kg; day 0–3 see Fig. 2A), resulting in Tsc1 deletion
in Cre+ mice. Mice received either vehicle (for baseline
assessment, see below) or treatment. All AEDs were daily
administered by intraperitoneal injections using hypoder-
mic-needle 25G 9 ypo mm (Sterican/B-Braun). Con-
centrations used for the AED treatments were based on
effective concentrations described in literature for various
animal models of epilepsy. Rapamycin (1, 3, 5 and 10 mg/
kg; LC Laboratories), clobazam (30 mg/kg20,21; Alliance
healthcare), tiagabine (40 mg/kg22; Sigma-Aldrich) and
AZD8055 (15 mg/kg23; Adooq Bioscience, A10114) were
dissolved in dimethyl sulfoxide (DMSO) (injection volume
1 lL/g). Vigabatrin (200 mg/kg24; Sanofi-Aventis B.V.)
was dissolved in 0.9% saline (injection volume 10 lL/g).
Lamotrigine (25 mg/kg25; Alliance healthcare) and valproic
acid (350 mg/kg26; Alliance healthcare) were27 dissolved in
sterilized water (injection volume 10 lL/g). The S6 kinase
inhibitor PF4708671 (75 mg/kg28; Sigma Aldrich,
1255517-76-0), was dissolved by adding a mixture of 10%
Tween-80 (Sigma Aldrich, 9005-65-6) to 40% DMSO. This
mix was vortexed vigorously and sonicated for several min-
utes until the drug was dissolved. With saline, the mixture
was adjusted to its final concentration and vortexed and/or
sonicated till it was fully dissolved (injection volume 3 lL/
g). The ketogenic diet with a nutrient distribution ratio of
4:1 of fat to protein and carbohydrates was given ad libitum
(E15149-30, Bio services ssniff EF R/M). Food consump-
tion and body weight was monitored daily for both stan-
dard diet- and ketogenic diet-fed mice. Ketone body levels
were measured for both groups by loading 1.5 lL venous
blood onto a ketone body testing strip (Freestyle Precision
Xtra, Abbott Diabetes Care).
Establishment of control cohort and
replication study
Seizure characteristics and survival of untreated mice as
presented in Figures 2 and 6, were calculated from com-
bined data of all vehicle-treated mice. To determine the
robustness of this baseline (e.g., due to genetic drift, or
differences with respect to surgery or analysis), we estab-
lished again a baseline at the very end of all drug-testing
studies, performed by a different experimenter (n = 20)
These results were completely overlapping (data not
shown), indicating that the phenotype is very robust and
can be assessed by different experimenters.
Analysis and statistics
Epilepsy onset, frequency, and survival were analyzed off-
line from the EEG recordings. For statistical analysis of
the onset and survival, a Kaplan–Meier (Log Rank) analy-
sis was performed. Correlation was tested with a Pearson
correlation test. Seizure frequency per 24 h was calculated
for each mouse, by averaging the total number of seizures
by the total number of days the mouse was epileptic. The
last day of seizures was excluded from this calculation.
The average of all the mice within each drug condition
was compared to the Tsc1-Cre+ group.
Western blot data and Pathscan data were analyzed
using a parametric unpaired t-test or a one-way ANOVA
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with a Dunnett’s post hoc test where the Tsc1-Cre– mice
or Tsc1-Cre+ were used as controls (control group is spec-
ified in the figure legend). All statistics were done with
GraphPad Prism (version 6, San Diego, CA). The results
and further details of the performed statistical tests for
the western blots, are presented in (Tables S1–S7). Error
bars represent standard errors of the mean (SEM) and P-
values < 0.05 were considered as significant. Group sizes
are indicated in each figure where n is the number of
mice used.
Results
Tsc1-Cre+ mice exhibit brain-specific Tsc1
deletion and mTORC1 hyperactivation
We started the characterization of the Tsc1f/f-Tg(Camk2a-
CreERT2) mouse model (for more details see the methods
section), hereafter called Tsc1-Cre+ or Tsc1-Cre– mice, by
examining whether the Tsc1 gene was effectively deleted
upon four consecutive daily tamoxifen injections. A poly-
merase chain reaction (PCR) analysis showed Tsc1 gene
deletion in the cortex and hippocampus of tamoxifen-
treated Tsc1-Cre+ mice, with no discernable deletion out-
side the brain (e.g. in the liver) Fig. 1A). We used the
phosphorylation of S6 (pS6Ser240/244), a specific down-
stream target of mTORC1,18 as a mTORC1 activity read-
out to further characterize our mouse model. Increased
pS6Ser240/244 levels were observed in DAB stainings of cor-
tical and hippocampal slices from Tsc1-Cre+ mice com-
pared to Tsc1-Cre– control mice (Fig. 1B). A strong co-
labeling of CAMK2A and pS6Ser240/244 was observed in
Tsc1-Cre+ mice, indicating that (nearly) all CAMK2A-pos-
itive excitatory neurons in the cortex (Fig. 1C) and hip-
pocampus (Fig. 1D) underwent Tsc1 gene deletion. In
contrast, stainings with parvalbumin, a marker for parval-
bumin-positive inhibitory neurons, did not show any co-
labeling with pS6Ser240/244 (Fig. 1C and 1). Overall, there
were no structural malformations observed. Furthermore,
and in line with our previous published Tsc1 mouse
model,4 we did not observe signs of astrogliosis. We did
observe bigger pyramidal neuron soma’s in Tsc1-Cre+
mice on day 12 after gene deletion (Tsc1-Cre– M:
129.8 lm2, SEM: 1.95; Tsc1-Cre+ M: 166.8 lm2, SEM:
2.75; T (288) = 11.16, P < 0.0001), which is a common
observation after mTORC1 hyper activity.29,30
To investigate how mTORC1 activity increased over
time after Tsc1 gene deletion, we performed western blot
analysis and investigated pS6Ser240/244 levels at different
time points. Tsc1-Cre+ and littermate control Tsc1-Cre–
mice, were sacrificed at day 4, 6, 8, or 13 after gene dele-
tion (first tamoxifen injection on day 0). Western blot
analysis confirmed significantly decreased TSC1 protein
levels in cortical and hippocampal lysates already at day 4
after gene deletion (Fig. 1E and 1; Table S1). Further-
more, a gradual increase of pS6Ser240/244 was observed
which reached statistical significance on day 6 in the cor-
tex and day 8 in the hippocampus. pS6Ser240/244 levels
reached a maximum on day 8 in both brain areas
(Fig. 1E and 1; Table S1). In addition, an increase in S6
expression itself was observed, indicating that its transla-
tion is also controlled by the mTORC1 pathway. Taken
together, this data show that we can successfully delete
Tsc1 in CAMK2A-expressing cells, resulting in cell-specific
activation of the mTORC1 pathway.
Acute loss of Tsc1 in adult excitatory
forebrain neurons leads to spontaneous
epilepsy and SUDEP
To examine whether Tsc1-Cre+ mice develop epilepsy after
Tsc1 deletion, we monitored brain activity continuously by
using a wireless EEG device from the day of the first tamox-
ifen injection. Analysis of the EEG recordings (Fig. 2B),
showed that all Tsc1-Cre+ mice developed epilepsy in a nar-
row time window between day 8 and day 12 after gene dele-
tion (median epilepsy onset is 10 days) (Fig. 2C). As shown
in Figure 1, day 8 is the time point where TSC1 protein
levels drop just below 50% and pS6Ser240/244 reaches its
maximum. The Tsc1-Cre+ mice suffered from tonic–clonic
seizures, characterized by generalized limb clonus and loss
of upright posture. During the postictal phase, mice
showed immobilized behavior for several seconds. All Tsc1-
Cre+ mice died between 12 and 18 days (median 15 days;
Figure 1. Cre-mediated Tsc1 gene deletion in CAMK2A-expressing neurons induces hyperactivation of the mTORC1 pathway. (A) Tsc1 PCR
analysis of DNA isolated from the cortex, hippocampus, and liver after four tamoxifen (Tam) injections, inducing efficient and brain-specific Tsc1
gene deletion of mice sacrificed at day 11. The higher band indicated with ‘–’ represents the knock-out allele; the lower band ‘f’ represents the
floxed (nondeleted) allele. (B) Immunohistochemistry (DAB staining) on sagittal sections of an adult Tsc1-Cre+ and Tsc1-Cre– mouse, 13 days after
gene deletion stained for pS6Ser240/244. Increased levels of pS6Ser240/244 in tamoxifen injected Tsc1-Cre+ mice are observed. (C and D) Fluorescent
immunohistochemistry on coronal sections of Tsc1-Cre+ for pS6Ser240/244 shows high colocalization with CAMK2A (green) but not with
parvalbumin (PV; red), in the cortex and hippocampus. (E and F) Tsc1-Cre+ mice show TSC1 reduction and increased levels of S6 and pS6Ser240/244
starting at day 6 after gene deletion in the cortex and hippocampus. Western blot data are presented as means with error bars representing SEM.
Sample sizes are indicated in the figures with n the number of mice used. A one-way ANOVA was used for statistical analysis with a Dunnett’s
post hoc test. Tsc1-Cre+ mice were used as control group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Fig. 2D) after a tonic–clonic seizure, characterized by
abrupt flattening of the EEG correlated with immobilized
behavior and at death (Fig. 2B arrow). Seizure frequency
increased slightly over time with a striking variability
(Fig. 2E). All seizures, including the lethal ones, lasted on
average around 40 sec (Fig. 2F and G). Notably, death of
the animal was entirely unpredictable, reminiscent of sud-
den unexpected death in epilepsy (SUDEP). Specifically,
there was no correlation between the day of seizure onset
and the day of death (Fig. 2H; (r = 0.34; n = 20; P = 0.12).
Neither between seizure frequency and day of death
(r = 0.09; n = 20; P = 0.69), nor the total number of sei-
zures and the day of death (r = 0.16; n = 20; P = 0.49),
and some animals even died at the very first seizure. Never-
theless, on average, seizure frequency increased over time
with one seizure per 24 h at the day of epilepsy onset
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Figure 2. Tsc1-Cre+ mice develop tonic–clonic seizures in a narrow time window without predictors for day of death. (A) Timeline of the
experimental setup. All mice received four tamoxifen injections followed by optional AED treatment starting on day 4 after initiating gene
deletion. Mice were sacrificed on day 12 or 13, 2 h after the last drug injection (B) Example traces of an EEG recording showing a baseline, a
seizure, and a lethal seizure trace. All lethal seizures showed a typical flattening EEG trace visualized in the zoom in trace. (C) EEG recordings
show that all Tsc1-Cre+ mice develop epilepsy between 6 and 12 days after initiation of gene deletion. (D) Tsc1-Cre+ mice died 12–18 days after
gene deletion. (E) Average seizure frequency increases over time after gene deletion, whereas average seizure duration does not increase
significantly over time (F). Plotted line is the average per day after gene deletion of all mice. (G) Seizure duration is not different between the day
of onset and the day of death. (H) Correlation plot of day of death and day of seizure onset, showing no correlation. (I) Correlation plot of day of
death and number of seizures the day before death, showing no correlation. (J) Correlation plot of day of death and total number seizures per
mouse indicating no correlation. EEG recordings of animals were only taken into account if the indicated parameter could be unambiguously be
assessed. This is the case for minimally 16 animals (day of seizure onset) and maximally 20 animals (average seizure duration per animal). The
dots represent averages of individual mice.
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(median day 10), up to a median frequency to five seizures
per 24 h preceding death (Fig. 2I and J).
In sum, biallelic Tsc1 gene deletion in adult mice
results in epilepsy in a specific time window with increas-
ing frequency over time and no change in seizure dura-
tion. Furthermore, none of the investigated parameters
could predict the day of death, resembling SUDEP.
Tsc1 loss-driven epileptogenesis is
dependent on RHEB1 activation
To further confirm the mTORC1 dependency of the phe-
notypes observed in our mouse model, we crossed our
Tsc1f/f-Tg(CaMK2A-CreERT2) mice with a Rheb1f/f mouse
line.19 A conditional brain-specific double homozygous
mouse model was obtained, where both Tsc1 and Rheb1
could be deleted in CAMK2A-positive neurons by tamox-
ifen injections (hereafter called Tsc1-Rheb1-Cre+). We have
previously shown that deletion of Rheb1 from CAMK2A-
positive cells, significantly reduces mTORC1 activity (mea-
sured by the level of pS6), indicating that RHEB1 activa-
tion is the critical step for mTORC1 activation.19
In contrast to the Tsc1-Cre+ mice, Tsc1-Rheb1-Cre+
mice did not develop epilepsy, appeared healthy and
showed normal survival until the last day of observation
(n = 4, day 30 from the first day of tamoxifen injection
(data not shown). To confirm the deletion of Rheb1 and
Tsc1 genes and to assess the effect on the mTORC1 path-
way, we performed western blot analysis on cortex and
hippocampus on day 12 after the first tamoxifen injec-
tion. We observed significantly reduced levels of the
RHEB1 and TSC1 protein, confirming the successful gene
deletion (Fig. 3A and 3; Table S2). In addition, the level
of pS6Ser240/244 in Tsc1-Rheb1-Cre+ mice was significantly
lower than Tsc1-Cre+ mice and was not different from
Tsc1-Cre– mice or the rapamycin (10 mg/kg)-treated
Tsc1-Cre+ mice. These results confirm that the pheno-
types observed in our Tsc1-Cre+ mice are specifically
dependent on RHEB1-mediated mTORC1 activation.
Epileptogenesis driven by the loss of Tsc1
shows a dose-dependent response to
mTORC1 inhibitor rapamycin
Previous studies showed that rapamycin treatment effec-
tively rescues and/or prevents seizures in TSC mouse
models.4,31–34 To test the efficacy of rapamycin in our
model, we treated mice with different doses of rapamycin,
starting 4 days after initiation of gene deletion. The effect
on epilepsy onset, epilepsy frequency, and animal survival
was analyzed. Of the mice treated with 1 mg/kg rapamy-
cin, 80% developed epilepsy. A dose of 3 mg/kg resulted
in epilepsy in 60% of the mice and 5 mg/kg showed
epilepsy in 20% of the mice. Treatment with 1 mg/kg
rapamycin had no effect on the onset and on survival,
while treatment with a dose of 3 or 5 mg/kg significantly
delayed epilepsy onset and significantly extended survival
(Fig. 4A and 4; Table S3). Furthermore, seizure frequency
was reduced in a dose-dependent manner (Fig. 4C;
Table S3). Mice treated with 10 mg/kg rapamycin, did
not develop epilepsy and survived throughout the dura-
tion of the experiment (data not shown). These results
show the antiepileptogenic effects of rapamycin.
To assess whether the dose-dependent effect of rapamy-
cin on epilepsy in Tsc1-Cre+ mice was reflected by the level
of mTORC1 activity, we measured pS6Ser240/244 protein
levels in Tsc1-Cre+ mice treated with either vehicle or differ-
ent concentrations of rapamycin. As expected, pS6Ser240/244
levels increased significantly in vehicle-treated mice. Inter-
estingly, treatment with rapamycin 1 mg/kg of rapamycin
lowered pS6Ser240/244 in hippocampus and cortex, but this
level was still well above Tsc1-Cre– control mice. In con-
trast, doses of 3 mg/kg rapamycin or higher seemed to be
more effective as both reduced pS6Ser240/244 levels near (or
even below) control levels (Fig. 4D and 4; Table S3).
Taken together, these results show that epilepsy severity
as measured by onset time, seizure frequency, and animal
survival in this TSC mouse model, is directly related to
the degree of neuronal mTORC1 activity.
Molecular analysis indicates changes in
4E-BP1/2, RSK1 and AMPK activity
To study which proteins besides pS6 are dysregulated
during epileptogenesis in Tsc1-Cre+ mice, we performed a
limited analysis of phosphorylated proteins in the TSC-
mTORC1 pathway (Fig. 5A). By using an antibody array,
we assessed the phosphorylation of the following proteins:
Akt (T308, S473), S6 (S235/236), AMPK-a (T172),
PRAS40 (T246), mTOR(S2481), GSK-3a (S21), GSK-3b
(s9), p70S6K (T389, T421/S424), BAD (S112), RSK1
(S380), PTEN (S380), PDK1 (S241), ERK1/2 (T202/204),
and 4E-BP1 (T37/46). Because the vast majority of Tsc1-
Cre+ mice developed epilepsy around day 8 and onward,
we were in particularly interested in the proteins that
would show increased phosphorylation at this time point.
Furthermore, day 13 was examined as well, to assess the
effect of epilepsy on phosphorylation of the aforemen-
tioned proteins. Lastly, we wanted to know if treatment
with rapamycin could minimize the phosphorylation of
these proteins, comparable to control levels. To that end,
mice were divided into four groups: (I) a control group
of Tsc1-Cre– mice, (II) Tsc1-Cre+ mice treated with vehi-
cle and sacrificed on day 8 or (III) on day 13, and (IV)
Tsc1-Cre+ mice treated with rapamycin (5 mg/kg) sacri-
ficed on day 13. Out of the tested proteins, only pS6Ser235/
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236, p4E-BP1Thr37/46, pRSK1Ser380, and pAMPKThr172
showed a significant upregulation in both cortex and hip-
pocampus, and responded to rapamycin treatment. Of
these four proteins, only pS6Ser235/236 (cortex and hip-
pocampus) and pRSK1Ser380 (only cortex) were significantly
elevated around epilepsy onset (day 8) (Fig. 5B and C;
Table S4). p4E-BP1Thr37/46, and pAMPKThr172 were only
significant increased at day 13. Although the four proteins
all responded to rapamycin treatment in the cortex, this
was not the case for the hippocampus. Levels of p4E-
BP1Thr37/46, pRSK1Ser380, and pAMPKThr172 remained sig-
nificantly increased, despite the high dose of rapamycin
treatment used (Fig. 5C; Table S4).
Pretreatment with AEDs does not prevent
epileptogenesis
A clinical relevant advantage of our mouse model is
the ability to investigate if treatment with AEDs before
seizure onset could be antiepileptogenic by preventing
or delaying the onset of epilepsy, as well as preventing
the molecular changes that are induced upon Tsc1
gene deletion, in a similar way as rapamycin does. If
a drug does not have such an effect, the seizure sup-
pressive properties can further be investigated by
determining the effect on seizure frequency as well as
survival time.
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We tested three main GABAergic drugs, increasing neu-
ronal inhibition: vigabatrin (200 mg/kg), clobazam
(30 mg/kg), and tiagabine (40 mg/kg). Furthermore, two
drugs were tested that mainly lower neuronal excitation:
valproic acid (350 mg/kg) and lamotrigine (25 mg/kg).35
Vigabatrin and Valproic acid are commonly used to treat
infantile spasms including those in TSC-infants.12,36 Tsc1-
Cre+ mice received daily drug injections starting on day 4
after gene deletion. At this time point, TSC1 protein levels
are still above 50% and it is well before the mice show a
first seizure. Vehicle-treated Tsc1-Cre+ mice were used as
control. Despite initiating treatment well before seizure
onset, all mice developed epilepsy, and none of the drugs
was able to prevent seizure-related lethality (Fig. 6A and B,
Table S5). Importantly, all drugs reduced the average sei-
zure frequency, but due to the high variability combined
with relative small group sizes, this effect did not always
reach statistical significance (Fig. 6C).
Vigabatrin had the largest effect on seizure frequency
and was the only drug that was able to significantly delay
seizure onset and lower seizure frequency. Valproic acid
did not delay seizure onset, but significantly improved
survival. In contrast, lamotrigine significantly worsened it
by showing an earlier onset and lethality. Clobazam also
showed a significant earlier onset of seizures and a ten-
dency toward decreased survival.
Given that vigabatrin was more effective than compara-
ble drugs that increase neuronal inhibition (clobazam and
tiagabine), we tested the effect of these drugs on
mTORC1 signaling. Treated mice were sacrificed on day
12 and phosphorylation of pS6Ser240/244 in cortical and
hippocampal tissues was assessed by western blots analysis
(Fig. 6D and 6). pS6Ser240/244 levels remained high in all
treatments, indicating that none of the drugs had an
effect on mTORC1 pathway activity (Fig. 6D and 6;
Table S5).
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Ketogenic diet delays seizure onset and
extends survival, but does not lower seizure
frequency
It has been shown that ketogenic diet can be beneficial
for treating TSC-related epilepsy.15,37 To test the efficacy
of the ketogenic diet in our mouse model, Tsc1-Cre+ mice
were first fasted for 18 h and were placed on a ketogenic
diet 6 weeks before Tsc1 gene deletion. Within these
6 weeks, the mice were fully used to the diet having a sta-
bilized calorie intake and a ketone body-based metabo-
lism.38 Treatment was continued until the end of the
experiment. Ketone bodies were measured on day 13 just
before decapitation, and were significantly higher in mice
on the ketogenic diet than in mice fed with standard diet.
This indicates that ketosis had replaced a glucose-based
metabolism in these mice (Table S6). Although the keto-
genic diet was not able to significantly lower seizure fre-
quency (Fig. 7C), epilepsy onset showed a small but
significant delay and mice on a ketogenic diet lived signif-
icantly longer than mice on a standard diet (Fig. 7A and
7; Table S6), Moreover, pS6Ser240/244 was significantly
lower in mice treated with the ketogenic diet, but this
effect was only observed in the cortex. Besides, the phos-
phorylation levels in the ketogenic diet-fed mice were still
higher than Tsc1-Cre– control animals (Fig. 7E and 7;
Table S6).
AZD8055 and PF4708671 do not improve the
epilepsy phenotype
We tested the effects of two novel compounds, AZD8055
and PF4708671 in our Tsc1 mouse model. The first drug,
AZD8055 is an ATP-competitive dual mTOR inhibitor
inhibiting both mTORC1 and mTORC2.23 The second
drug, PF4708671 is a specific S6K1 inhibitor, a down-
stream target of mTORC1.39 Because rapamycin could
successfully prevent and treat epilepsy by inhibiting
mTORC1 activity and reducing S6 phosphorylation, we
hypothesized that AZD8055 would be equally or even
more effective in treating or preventing epilepsy in Tsc1-
Cre+ mice. If S6K has a key role in epileptogenesis, the
S6K inhibitor PF4708671 might also be able to inhibit
epileptogenesis in this Tsc1 mouse model. To study the
possible antiepileptic effects of these compounds, mice
were treated daily with either AZD8055 (15 mg/kg) or
PF4708671 (75 mg/kg) starting 4 days after initiation of
gene deletion, and seizures were monitored by EEG. Sur-
prisingly, both drugs did not show an effect on epilepsy
onset or survival (Fig. 8A and 8). Although not signifi-
cant, the drugs seem to lower average seizure frequency
per mouse (Fig. 8C and 8; Table S7).
To establish that both drugs crossed the blood–brain
barrier and lowered mTORC1/2 or S6K activity, we per-
formed a western blot analysis. Mice were sacrificed
12 days after gene deletion and pS6Ser240/244 levels were
assessed in hippocampal and cortical tissue of Tsc1-Cre–
mice, vehicle-treated Tsc1-Cre+ mice, AZD8055-treated
mice, and PF4708671-treated mice. In addition, protein
levels of pAkt were used as a read-out of the mTORC2
pathway of the AZD8055-treated mice. Despite having no
effect on epilepsy, pS6Ser240/244 levels were reduced to
Tsc1-Cre– control levels in the hippocampus and cortex of
AZD8055-treated Tsc1-Cre+ mice, indicating a strong
inhibition of the mTORC1 pathway. Although statistically
not significant, levels of pAkt(473) were also much lower
in the AZD8055-treated mice (Fig. 8E and 8; Table S7).
Brain tissue of PF4708671-treated mice revealed slightly
lower levels of pS6Ser240/244 in the hippocampus, but levels
did not turn back to the levels observed in Tsc1-Cre-
mice. Moreover, no effect of PF4708671 was observed in
the cortex (Fig. 8G and 8; Table S7).
Taken together, treatment with AZD8055 normalized
mTORC1 and mTORC2 activity while it did not improve
the epileptic phenotype. Treatment with PF4708671 failed
to normalize mTORC1 signaling as well as the epilepsy
phenotype.
Discussion
Poor responsiveness to AEDs is a major problem for
patients with epilepsy in general, but in particular for
TSC patients of which the majority do not respond to
drug therapy.11,12,40 Rather than just suppress seizures,
treatment should ideally interfere with the process of
epileptogenesis.
Previous studies showed that Tsc1 deletion in different
cell types can result in epilepsy, for example, local Tsc1
deletion in CAMK2A-expressing neurons,41–43 or Tsc1
deletion specifically in glial cells.34 Although these models
are of great value, they are not very suitable to study the
process of TSC/mTOR-associated epileptogenesis as sei-
zure onset is unpredictable and poorly controlled. To get
more insight into the process of mTORC1-driven epilep-
togenesis, we previously developed a model where the
Tsc1 gene was conditionally deleted in all cells. The
somatic deletion of Tsc1 in all cells, including the periph-
eral tissue, resulted in severe epilepsy. However, these
mice also suffered from other health issues resulting in
lethality unrelated to epilepsy, limiting their usefulness.4
Therefore, we developed and characterized a new Tsc1
mouse model. In this model, the Tsc1 gene is acutely
deleted and limited to CAMK2A-expressing cells, which
in the forebrain is restricted to excitatory neurons. This
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model showed seizure onset in a narrow time window
(10  2 days) upon gene deletion.
Characterizing the epileptic seizures in our inducible
mouse model, we observed tonic–clonic seizures with
generalized limb clonus and loss of upright posture, simi-
lar to previously reported TSC mouse models.18,34 Aver-
age seizure duration remained quite constant, whereas
average seizure frequency increased over time. Despite the
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highly distinct time window in which seizures started, sei-
zure frequency varied greatly between animals as well as
within animals.
Reminiscent of SUDEP, none of the investigated
parameters (seizure onset, frequency, and duration) could
predict the day of death. In fact, all mice died after a sei-
zure and some even after the very first seizure. Moreover,
the lethal seizure was also not longer than the very first
seizure. Importantly, SUDEP is one of the leading causes
of seizure-related death and contributes substantial to the
cause of death in patients who die from complications of
TSC.44,45 Besides, SUDEP cases were described in 10% of
the families who carried mutations in genes of the
GATOR1 complex, a regulator of the mTOR pathway.46
Characteristics of SUDEP are generalized tonic–clonic sei-
zures and abrupt flattening of EEG patterns, where death
is probably related to brainstem spreading depolariza-
tion.45,47–51 This acute flattening of the EEG is also
observed in our recordings and is likely responsible for
the lethality, given that the gene deletion is brain specific.
Lamotrigine significantly shortened survival in our mice,
which is noteworthy as it has been suggested that lamot-
rigine could facilitate SUDEP.45,48,52
At the molecular level, we observed a strong increase in
mTORC1 activation after Tsc1 deletion, as measured by
the phosphorylation of S6, a downstream target of
mTORC1. Seizures and associated lethality were fully pre-
vented by genetic (RHEB1 deletion) or pharmacological
(rapamycin) blockade of the mTORC1 pathway. In line
with other studies, rapamycin prevented epilepsy in a
dose-dependent manner in our TSC1 mouse model.4,31–34
To identify future treatment targets, we further assessed
the phosphorylation of proteins that are related/linked to
the mTORC1 pathway. We observed a significant upregu-
lation of pS6Ser240/244, p4E-BP1Thr37/46, pRSK1Ser380, and
pAMPKThr172 in both the cortex and hippocampus. Rapa-
mycin treatment at 5 mg/kg reduced the phosphorylation
of all these proteins in the cortex, although p4E-BP1Thr37/
46, pRSK1Ser380, and pAMPKThr172 remained significantly
increased in the hippocampus at this dose. Notably, p4E-
BP1Thr37/46 and pAMPKThr172, were only significantly
increased at day 13. Although rapamycin treatment at
5 mg/kg reduced seizures, it did not reduce p4E-BP1Thr37/
46 and pAMPKThr172 levels in the hippocampus. Taken
together, these results suggest that these proteins are not
key players in the mechanisms underlying epilepsy. Relat-
ing these findings to literature, it appears that 4E-BP
plays distinct roles in TSC-driven cortical migration dur-
ing development and in TSC-driven epilepsy.53 Upstream
of mTORC1, AMPK1 can phosphorylate TSC2 and Rap-
tor, leading to mTORC1 inhibition. AMPK1 is activated
by phosphorylation of the Threonine 172, which is medi-
ated by CAMK2B and Serine/threonine kinase 11 (STK11;
also known as Liver Kinase B1 (LKB1)).54,55 This supports
the notion that increased pAMPKThr172 phosphorylation
at day 13 is a secondary response, induced either by the
epilepsy itself, or by a feedback mechanism in reaction to
the high mTORC1 levels.
Rapamycin showed strong antiepileptogenic properties
in our mice: at higher doses, seizures were absent, lethal-
ity was not observed, and molecular changes were absent.
Although rapamycin treatment of TSC patients has been
shown to be effective in some cases treating epi-
lepsy,13,14,56 the clinical effects are not as striking as the
results seen in our mice. Since treatment with rapamycin
in patients is typically initiated after a long period of epi-
lepsy, other mechanisms may have been altered and unre-
sponsive to rapamycin treatment. This might explain the
observed variable responses in patients. In addition, our
(acute) inducible Tsc1 mouse model does not model the
epilepsy that is generated by aberrant neuronal migration
(tuber formation), which is observed in many patients.
Nevertheless, our mouse model does have important clin-
ical value, showing that loss of a functional TSC complex
in excitatory neurons is sufficient to induce epilepsy, even
in the absence of developmental changes.
Out of the tested AEDs, vigabatrin showed the largest
improvements on the epileptic phenotype in the TSC
mice. Vigabatrin is known as a first-line treatment in
infantile spasm including TSC patients.10 It was the only
AED within this study that was able to significantly delay
seizure onset. Vigabatrin did not affect mTORC1 signal-
ing, hence it is not truly antiepileptogenic and the basis
of beneficial effect of vigabatrin remains to be identified.
Figure 6. Preventive treatment with traditional AEDs reveal variable responses and do not affect the mTORC1 pathway. (A) Seizure onset of
Tsc1-Cre+ mice treated with the AEDs at 4 days after initiation of gene deletion, days before seizure onset. Tsc1-Cre+ mice were treated with
vigabatrin (200 mg/kg), clobazam (30 mg/kg), tiagabine (40 mg/kg), valproic acid (350 mg/kg), or lamotrigine (25 mg/kg). (B) Survival curves of
the Tsc1-Cre+ mice treated with the different AEDs. (C) Average seizure frequency of the different drug treatments in Tsc1-Cre+ mice. Each line
represents the average number of seizures per mouse with the squares indicating the day of onset and the triangles the day of death. (D and E)
Cortical and hippocampal western blot data from a separate group of mice of the different treatment conditions of mice sacrificed on day 12,
2 h after the last drug injection. None of the used drugs are able to lower pS6Ser240/244. Behavior was analyzed with a Kapler–Meier Log Rank
test. Seizure frequency was compared with an unpaired t-test or a nonparametric Mann–Whitney test. Western blot data are presented as means
with error bars representing SEM. Sample sizes are indicated in the figures. A one-way ANOVA was used for statistical analysis with a Dunnett’s
test as post hoc test. Tsc1-Cre+ mice were used as control group. *P < 0.05, **P < 0.01, ****P < 0.0001.
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Interestingly, valproic acid did not delay seizure onset,
but had a small but significant effect on survival. This
drug enhances the GABAergic system, but also acts on
different classes of voltage gated ion channels and on the
NMDA receptors.57 The broad working mechanism of
this AED makes it difficult to determine what mechanism
contributes to the increased survival.
Another treatment that can be quite effective for TSC
patients, is the ketogenic diet15,37 as well as the related
low glycemic index treatment.58 We confirmed the effi-
cacy of the ketogenic diet by showing delayed seizure
onset and extended survival in ketogenic diet-treated TSC
mice. The precise mechanism of the ketogenic diet is still
under investigation, but there could be a mechanistic link
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Figure 7. Ketogenic diet reduces cortical mTORC1 activity, delays epilepsy onset, and improves survival. (A) Seizure onset curves of Tsc1-Cre+
mice treated with the ketogenic diet (Cre+/KD) or standard diet (Cre+/SD). The KD-fed mice were on the diet for 6 weeks before gene deletion.
Seizure onset is significantly delayed in Cre+/KD mice. (B) Survival curve of the Cre+/KD and Cre+/SD mice. (C) Each line represents the average
number of seizures per mouse with the squares indicating the day of onset and the triangles the day of death. (E and F) Western blot analysis of
hippocampal and cortical tissue of an independent group of mice sacrificed on day 13. Significantly lower levels of cortical pS6Ser240/244) in the
Cre+/KD mice are found. Seizure onset and survival were analyzed with a Kapler–Meier Log Rank test. Seizure frequency was compared with an
unpaired t-test. Western blot data is presented as means with error bars representing SEM. Sample sizes are indicated in the figures with n the
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Figure 8. Preventive treatment with AZD8055 and PF4708671 does not improve the epileptic phenotype despite reduced levels of pS6Ser240/244.
(A) Seizure onset graph of Tsc1-Cre+ mice treated with vehicle, AZD8055 (15 mg/kg), or PF4708671 (75 mg/kg) started 4 days after initiation of
gene deletion. (B) Survival curves of the Tsc1-Cre+ mice treated with AZD8055 and PF4708671. (C and D) Average seizure frequency is not
different between the treated mice and control mice. Each line represents the average number of seizures per mouse with the squares indicating
the day of onset and the triangles the day of death. (E and F) Western blot of cortical and hippocampal tissue of an independent group of mice
treated with AZD8055 sacrificed on day 12, 2 h after the last drug injection. Levels of pS6Ser240/244 are significantly lower in the cortex and
hippocampus of the AZD8055-treated mice. Although statistically not different, lower levels of pAkt are observed in AZD8055-treated mice. (G)
Mice treated with PF4708671 show significant lower pS6Ser240/244 levels in the hippocampus. Seizure onset and survival were analyzed with a
Kapler–Meier Log Rank test. Average frequency was compared with a one-way ANOVA and Dunnett’s post hoc test. Western blot data is
presented as means with error bars representing SEM. Sample sizes are indicated in the figures with n the number of mice used. Blots shown are
representative but in some cases the order of the samples was adjusted to allow alignment with the corresponding bar. A one-way ANOVA was
used for statistical analysis with a Dunnett’s test as post hoc test. Tsc1-Cre + mice were used as control group. *P < 0.05, ***P < 0.001,
****P < 0.0001.
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between ketogenic diet and mTOR, through amino acid
metabolism, which acts upon mTOR signaling.59,60 In line
with these findings, we observed lower pS6 levels in our
mice, although levels remained significantly higher than
controls.
To identify novel treatments and get more insight in
the downstream targets of mTORC1, we tested two drugs
that affect mTORC1 signaling: AZD8055 and PF4708671.
The first drug, a dual mTOR inhibitor AZD8055 was pre-
viously used to investigate its effect on glioma develop-
ment. Treatment with AZD could successfully slow down
the growth of tumors and gliomas by inhibiting the
mTOR complex.23,53 Furthermore, the fact that another
dual mTOR inhibitor (PQR620) was effectively able
to improve epilepsy in a mouse model of chronic epi-
lepsy,61 suggests that this dual mTOR inhibitor might
have a beneficial effect. Comparable to rapamycin treat-
ment, AZD8055 treatment resulted in a strong reduction
of pS6Ser240/244. Furthermore, it reduced the protein levels
of pAkt(473). In contrast, the reduction in seizure fre-
quency was rather modest and no effect on seizure onset
and survival was observed. A possible explanation for this
negative finding could be attributed to the half-life of
AZD8055, which is 2–3 h in blood plasma62. However,
detailed analysis of the EEG data did not reveal a differ-
ence in total number of seizures in the 2 h after drug
injection compared to any of the other 2-h windows
within 24 h following injection. A second explanation
could be that mTORC2 activation is neuroprotective
instead61,63,64 and hence, a decrease in mTORC2 reduces
the effectiveness of inhibiting mTORC1. The second
specific drug that we tested, PF4708671, is a cell-perme-
able inhibitor of p70 ribosomal S6 kinase (S6K1 isoform).
It was previously shown that mTORC1 activity in a Tsc1
heterozygous knock out mouse, could be successfully
reduced by PF4708671 treatment.28 We observed a mod-
est reduction of pS6Ser240/244 in hippocampus, but not in
the cortex, and no effect on epilepsy. Possibly, at the con-
centration used, the drug was not able to counteract the
strong mTORC1 increase seen in our mice. Further inves-
tigation into the downstream mTORC1 targets remains
necessary to identify novel treatments.
In conclusion, we present a novel TSC-mTORC1-depen-
dent epilepsy model with high construct and face validity.
We demonstrate the translational value of this model for
drug testing by confirming clinical observations that viga-
batrin, ketogenic diet, and rapamycin are among the most
effective treatments for TSC-associated epilepsy. We prove
that these therapies (vigabatrin, ketogenic diet, and rapa-
mycin) are most efficient in our mouse model affecting sei-
zure onset, survival, and seizure frequency. Moreover, the
model can be used to study the mechanisms underlying
SUDEP as well as the mechanisms underlying
epileptogenesis. The fact that vigabatrin improves all the
epilepsy parameters in our mouse model suggests this treat-
ment can indeed be suitable to treat TSC patients and
delay/prevent epilepsy as seen in some clinical trials.16.
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Table S1. Statistics figure 1 – “Cre mediated Tsc1 gene
deletion in CAMK2A expressing neurons induces hyper
activation of the mTORC1 pathway”.
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Table S2. Statistics figure 3 – “Simultaneous deletion of
Tsc1 and Rheb1 prevents mTORC1 epileptogenesis and
mTORC1 activation”.
Table S3. Statistics figure 4 – “Rapamycin improves the
epileptic phenotype in Tsc1-Cre + mice in a dose depen-
dent manner”.
Table S4. Statistics figure 5 – “TSC1-mediated epilepsy
induces changes in the mTORC1-pathway that are only
partially reversed by rapamycin”.
Table S5. Statistics figure 6 – “Preventive treatment with
traditional AEDs reveal variable responses and do not
affect the mTORC1 pathway”.
Table S6. Statistics figure 7 – “Ketogenic diet reduces cor-
tical mTORC1 activity, delays epilepsy onset and
improves survival”.
Table S7. Statistics figure 8 – “Preventive treatment with
AZD8055 and PF4708671 does not improve the epileptic
phenotype despite reduced levels of pS6Ser240/244”.
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